Carlos Fernández de Larrea
@fdezdelarrea.bsky.social
Hematologist. Myeloma, macroglobulinemia, amyloidosis. Immunotherapy, CAR-T cells. Hospital Clínic de Barcelona. IDIBAPS. Universitat de Barcelona
🚀🧬 Forge your future in science at IDIBAPS and the Hospital Clínic of Barcelona! Join our pioneering CAR-T research team and work towards your PhD. We're seeking bright minds eager to advance cancer therapy.
🔗 www.clinicbarcelona.org/uploads/medi...
#CAR-T #MultipleMyeloma #CancerResearch 🧪🔬
🔗 www.clinicbarcelona.org/uploads/medi...
#CAR-T #MultipleMyeloma #CancerResearch 🧪🔬
www.clinicbarcelona.org
March 14, 2025 at 6:51 PM
🚀🧬 Forge your future in science at IDIBAPS and the Hospital Clínic of Barcelona! Join our pioneering CAR-T research team and work towards your PhD. We're seeking bright minds eager to advance cancer therapy.
🔗 www.clinicbarcelona.org/uploads/medi...
#CAR-T #MultipleMyeloma #CancerResearch 🧪🔬
🔗 www.clinicbarcelona.org/uploads/medi...
#CAR-T #MultipleMyeloma #CancerResearch 🧪🔬
Reposted by Carlos Fernández de Larrea
Presenten el primer model per predir la resposta a la teràpia amb cèl·lules #CART en #mieloma múltiple
https://s.mtrbio.com/bzqeztfpaf @fdezdelarrea.bsky.social
https://s.mtrbio.com/bzqeztfpaf @fdezdelarrea.bsky.social
February 4, 2025 at 9:02 AM
Presenten el primer model per predir la resposta a la teràpia amb cèl·lules #CART en #mieloma múltiple
https://s.mtrbio.com/bzqeztfpaf @fdezdelarrea.bsky.social
https://s.mtrbio.com/bzqeztfpaf @fdezdelarrea.bsky.social
Reposted by Carlos Fernández de Larrea
The ➡️Myeloma, amyloidosis, macroglobulinemia and other gammapathies⬅️ group led by Carlos Férnandez De Larrea studies the mechanisms that cause people with asymptomatic or premalignant monoclonal gammopathies to develop
👉https://s.mtrbio.com/dtaulqwzoa
👉https://s.mtrbio.com/dtaulqwzoa
Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.
s.mtrbio.com
December 29, 2024 at 7:02 PM
The ➡️Myeloma, amyloidosis, macroglobulinemia and other gammapathies⬅️ group led by Carlos Férnandez De Larrea studies the mechanisms that cause people with asymptomatic or premalignant monoclonal gammopathies to develop
👉https://s.mtrbio.com/dtaulqwzoa
👉https://s.mtrbio.com/dtaulqwzoa
Reposted by Carlos Fernández de Larrea
🆕Avenços en immunoteràpia CAR-T per evitar les recaigudes en mieloma múltiple
Un equip del #CLÍNIC-#IDIBAPS han introduït una modificació a les CAR-T que fa la seva resposta més duradora en models animals i cel·lulars
👉https://s.mtrbio.com/znabknfoyr
Un equip del #CLÍNIC-#IDIBAPS han introduït una modificació a les CAR-T que fa la seva resposta més duradora en models animals i cel·lulars
👉https://s.mtrbio.com/znabknfoyr
December 30, 2024 at 12:01 PM
🆕Avenços en immunoteràpia CAR-T per evitar les recaigudes en mieloma múltiple
Un equip del #CLÍNIC-#IDIBAPS han introduït una modificació a les CAR-T que fa la seva resposta més duradora en models animals i cel·lulars
👉https://s.mtrbio.com/znabknfoyr
Un equip del #CLÍNIC-#IDIBAPS han introduït una modificació a les CAR-T que fa la seva resposta més duradora en models animals i cel·lulars
👉https://s.mtrbio.com/znabknfoyr
Reposted by Carlos Fernández de Larrea
🆕Advances made in CAR-T immunotherapy to prevent relapse in multiple myeloma
A team from #CLÍNIC-#IDIBAPS has introduced a modification to a CAR-T that makes it more durable, according to results obtained in animal and cellular models
👉https://s.mtrbio.com/jsaizukynw
A team from #CLÍNIC-#IDIBAPS has introduced a modification to a CAR-T that makes it more durable, according to results obtained in animal and cellular models
👉https://s.mtrbio.com/jsaizukynw
December 23, 2024 at 10:30 AM
🆕Advances made in CAR-T immunotherapy to prevent relapse in multiple myeloma
A team from #CLÍNIC-#IDIBAPS has introduced a modification to a CAR-T that makes it more durable, according to results obtained in animal and cellular models
👉https://s.mtrbio.com/jsaizukynw
A team from #CLÍNIC-#IDIBAPS has introduced a modification to a CAR-T that makes it more durable, according to results obtained in animal and cellular models
👉https://s.mtrbio.com/jsaizukynw
#ASH24 with friends and colleagues @hospitalclinic.bsky.social @ash-hematology.bsky.social @idibaps.bsky.social
December 8, 2024 at 4:12 PM
#ASH24 with friends and colleagues @hospitalclinic.bsky.social @ash-hematology.bsky.social @idibaps.bsky.social